阿立派唑与奥氮平应用于首发精神分裂症患者治疗中对其糖代谢的影响探讨
2015-01-31赵磊
赵磊
阿立派唑与奥氮平应用于首发精神分裂症患者治疗中对其糖代谢的影响探讨
赵磊
【摘要】目的 研究对首发精神分裂症患者采用阿立派唑与奥氮平对其体内糖代谢的影响差异。方法 选取我院收治的100例首发精神分裂症患者,分别采用不同药物治疗。对比两组患者糖代谢状况及体质量状况差异性。结果 在糖代谢异常与糖尿病两项上,观察组不良情况发生率均低于对照组。两组治疗前体质量与BMI情况对比,P>0.05,差异不具有统计学意义,治疗后对照组高于观察组,P<0.05,差异具有统计学意义。两组各项数据对比,P<0.05,差异具有统计学意义。结论 对于首发精神分裂症而言,奥氮平更易造成糖代谢异常,相对更宜采用阿立派唑治疗。
【关键词】奥氮平;阿立派唑;首发精神分裂症;糖代谢
作者单位:024000内蒙古赤峰市安定医院
To Explore the Glycometabolism Impact of Aripiprazole Tablets and Olanzapine Application for Patients With First Publish Schizophrenia
ZHAO Lei Chifeng City Anding Hospital in Inner Mongolia, Chifeng 024000, China
[Abstract]Objective To explore the glycometabolism impact of Aripiprazole Tablets and olanzapine application for patients with first publish schizophrenia. Methods Selected 100 patients with first-episode schizophrenia admitted in our hospital, respectively treatment with different drugs. Compared with sugar metabolism and body quality difference of two groups. Results On sugar metabolism and diabetes, incidence of adverse situation observation group were lower than the control group. Two groups of treatment quality of precursor and BMI, P>0.05, had difference statistically significance, after treatment the control group was better than the observation group, P<0.05, had difference statistically significance. Compared the data of two group, P<0.05, had difference statistically significance. Conclusion First-episode schizophrenia patients with olanzapine are more likely to cause sugar metabolic abnormalities, and therefore more appropriate uses aripiprazole tablets.
[Key words]Olanzapine, Aripiprazole tablets, First-episode schizophrenia, Sugar metabolism
随着临床医学的不断发展,在精神分裂治疗方面已经有了多种药物,但药物带来的不良反应也不容小觑。药物控制精神病可改善预后状况,但长期用药可能增加冠心病、高血压、糖尿病、脂代谢异常风险,并且对血糖产生波动影响[1]。研究阿立派唑与奥氮平应用于首发精神分裂症时对患者糖代谢的影响,具体报道如下。
1 资料和方法
1.1一般资料
选取我院2013年2月~2015年2月收治的100例首发精神分裂症患者,随机分为对照组及观察组,各50例。对照组中男28例,女22例;平均年龄(46.2±6.2)岁。观察组中男27例,女23例;平均年龄(45.4±5.8)岁。两组患者在性别、年龄上对比,P>0.05,差异不具有统计学意义。……p>
